CAS No.: | 1392275-56-7 |
---|---|
Formula: | C25h33n6o9p |
EINECS: | 805-448-8 |
Type: | Pharmaceutical Intermediates |
Appearance: | Powder |
Quality: | Refined |
Samples: |
---|
Customization: |
---|
Suppliers with verified business licenses
Product Name
|
Tenofovir Alafenamide Hemifumarate |
Appearance
|
white powder |
Assay
|
99%min, 98.0% --101.0% |
Test
|
HPLC
|
Certificate
|
ISO 9001
|
CAS
|
1392275-56-7 |
MF | C9H14N5O4P |
Storage Temperature |
Cool Dry Place
|
Tenofovir Alafenamide Fumarate is a nucleotide reverse transcriptase inhibitor and a prodrug of tenofovir. It was developed
for use in the treatment of HIV infection and chronic hepatitis B, and is applied in the form of tenofovir alafenamide fumarate
(TAF)
Tenofovir belongs to nucleotide analog reverse transcriptase inhibitors block HIV replication. It can Combine with other
antiretroviral drugs for the treatment of HIV-1 infection.
At 1-2 hours after ingestion, tenofovir achieved peak plasma concentrations. When taken with food, tenofovir increase the
bioavailability of about 40%. Tenofovir phosphonate intracellular half-life is about 10 hours, so every day can take a. The
drug is primarily filtered through the glomerulus and excreted through the renal tubule delivery system, and the 70-80% is
excreted through the urine in the primitive form.
Company Information
Our Certificate
Our Service
Our Research
Packaging & Logistics
Suppliers with verified business licenses